Investigating the pathogenic role of calpain proteases and the therapeutic potential of their inhibition in mice modelling Machado-Joseph disease
Human Molecular Genetics · 2026
DOI: 10.1093/hmg/ddaf196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2026. Verfasst von Katherine J Robinson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Motor Neuron Disease Research Centre, Macquarie Medical School, Macquarie University, Level 1, 75 Talavera Road, Sydney, NSW 2109, Australia. Hauptthemen laut MEDLINE: Machado-Joseph Disease, Calpain, Ataxin-3. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council, Macquarie University Research Excellence Scholarship, MJD Foundation and Sara Halvedene Foundation.
Abstract (Originalsprache)
Machado-Joseph disease (MJD, also known as spinocerebellar ataxia type-3) is a fatal disease characterised by motor impairments and the presence of aggregated ataxin-3, the protein affected in MJD, in degenerating brain regions. Ataxin-3 protein aggregates have previously been reported to contain both full-length ataxin-3 protein and shorter protein fragments, highlighting proteolytic cleavage as a pathogenic mechanism. Calpains, calcium-activated proteases, have been reported to cleave ataxin-3 and have been implicated in MJD pathogenesis. This study aimed to explore whether calpain proteases were overactive at early, pathogenesis-relevant timepoints in male transgenic CMVMJD135 mice modelling MJD and identify the timepoint of calpain overactivation through obtaining longitudinal plasma samples. We detected increased levels of cleaved αII-spectrin in plasma from MJD mice as early as 12 weeks of age, shortly after the onset of neurological symptoms. Cerebellar and brainstem tissue from 15-week-old mice was immunoblotted, revealing a trend towards increased levels of calpain 1, and increased cleavage of calpain substrates such as αII-spectrin, beclin-1 and TAR DNA binding protein 43 (TDP-43) within the cerebellum. Further, we found that short-term treatment of male MJD mice (from 10 to 12 weeks of age) with the calpain inhibitor compound calpeptin yielded improvements in neurological symptoms and reduced the presence of cleaved αII-spectrin in plasma and cerebellum tissue when compared to vehicle treated MJD males. Our findings suggest that calpain overactivity may be an early disease phenotype that contributes to neurodegeneration in transgenic CMVMJD135 mice modelling MJD, and that calpeptin warrants further investigation as a potential treatment for MJD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Motor Neuron Disease Research Centre, Macquarie Medical School, Macquarie University, Level 1, 75 Talavera Road, Sydney, NSW 2109, Australia.
- School of Rural Medicine, Charles Sturt University, Level 1, 1521 Forest Road, Orange, NSW 2800, Australia.
ORCID-Profile: Katherine J Robinson, Angela S Laird
Förderung
- Australian National Health and Medical Research Council
- Macquarie University Research Excellence Scholarship
- MJD Foundation and Sara Halvedene Foundation
Zitieren
APA
Robinson, K. J., Wright, A. L., Watchon, M., Kuriakose, A., Simo, I., & Laird, A. S. (2026). Investigating the pathogenic role of calpain proteases and the therapeutic potential of their inhibition in mice modelling Machado-Joseph disease. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf196
Vancouver
Robinson KJ, Wright AL, Watchon M, Kuriakose A, Simo I, Laird AS. Investigating the pathogenic role of calpain proteases and the therapeutic potential of their inhibition in mice modelling Machado-Joseph disease. Human Molecular Genetics. 2026. doi:10.1093/hmg/ddaf196
BibTeX
@article{Robinson2026,
author = {Robinson, Katherine J and Wright, Amanda L and Watchon, Maxinne and Kuriakose, Andrea and Simo, Ignacio and Laird, Angela S},
title = {Investigating the pathogenic role of calpain proteases and the therapeutic potential of their inhibition in mice modelling Machado-Joseph disease},
journal = {Human Molecular Genetics},
year = {2026},
doi = {10.1093/hmg/ddaf196}
}
EUVIMED